Market Overview

Oppenheimer on Serepta: Farkas Departure From FDA Is A Positive Signal For Eteplirsen Approval

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for SRPT

DateFirmActionFromTo
Dec 2016JP MorganInitiates Coverage OnOverweight
Dec 2016Goldman SachsInitiates Coverage OnNeutral
Oct 2016Morgan StanleyInitiates Coverage OnEqual-Weight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (SRPT)